CCC Diagnostics, Inc. today launched their new website, directhittest.com to support  the DirectHit^® Test Panel for Breast Cancer.  DirectHit is a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor’s response to four commonly prescribed classes of anti-cancer drugs.  The DirectHit Test Panel is the only diagnostic test which can predict the responsiveness of breast cancer patients to two classes of chemotherapy drugs, taxanes and capecitabine. In addition, DirectHit is significantly more accurate than existing tests for estrogen receptor and the HER-2/neu.  The new site allows patients and health care professionals easy access to information on all aspects of the DirectHit Test Panel, from ordering instructions to the latest news.  According to John Hughes, CEO of CCC Diagnostics, “. Our new website will help spread the word about The DirectHit Panel for Breast Cancer, which will help improve outcomes and quality of life for breast cancer patients.”

About CCC Diagnostics, Inc.

CCC Diagnostics, Inc. was formed in 2004 by a group of scientists from the Johns Hopkins University School of Public Health, and led by the late Dr. Paul O. P. Ts’o, the former Director of the school’s Biophysics Division.

CCC Diagnostics, Inc. actively integrates discoveries in diagnostic, therapeutic and information technologies to create innovative approaches to cancer disease management and to enhance the quality of life for cancer patients. Our strategy is to provide effective, personalized chemotherapy treatment recommendations, increasing life quality and decreasing cost through appropriate drug choice.

CCC Diagnostics is located in the Caton Research Park in Baltimore, MD